663 related articles for article (PubMed ID: 28202625)
1. Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE
Loo TM; Kamachi F; Watanabe Y; Yoshimoto S; Kanda H; Arai Y; Nakajima-Takagi Y; Iwama A; Koga T; Sugimoto Y; Ozawa T; Nakamura M; Kumagai M; Watashi K; Taketo MM; Aoki T; Narumiya S; Oshima M; Arita M; Hara E; Ohtani N
Cancer Discov; 2017 May; 7(5):522-538. PubMed ID: 28202625
[TBL] [Abstract][Full Text] [Related]
2. [Cellular senescence and chronic inflammation].
Ohtani N
Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(5):390-7. PubMed ID: 25744638
[TBL] [Abstract][Full Text] [Related]
3. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.
Yoshimoto S; Loo TM; Atarashi K; Kanda H; Sato S; Oyadomari S; Iwakura Y; Oshima K; Morita H; Hattori M; Honda K; Ishikawa Y; Hara E; Ohtani N
Nature; 2013 Jul; 499(7456):97-101. PubMed ID: 23803760
[TBL] [Abstract][Full Text] [Related]
4. Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma.
Yamagishi R; Kamachi F; Nakamura M; Yamazaki S; Kamiya T; Takasugi M; Cheng Y; Nonaka Y; Yukawa-Muto Y; Thuy LTT; Harada Y; Arai T; Loo TM; Yoshimoto S; Ando T; Nakajima M; Taguchi H; Ishikawa T; Akiba H; Miyake S; Kubo M; Iwakura Y; Fukuda S; Chen WY; Kawada N; Rudensky A; Nakae S; Hara E; Ohtani N
Sci Immunol; 2022 Jun; 7(72):eabl7209. PubMed ID: 35749514
[TBL] [Abstract][Full Text] [Related]
5. Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota.
Ohtani N; Hara E
Cancer Sci; 2021 Nov; 112(11):4433-4443. PubMed ID: 34533882
[TBL] [Abstract][Full Text] [Related]
6. Relationship between Obesity, Gut Microbiome and Hepatocellular Carcinoma Development.
Hara E
Dig Dis; 2015; 33(3):346-50. PubMed ID: 26045268
[TBL] [Abstract][Full Text] [Related]
7. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
Jiang JW; Chen XH; Ren Z; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
[TBL] [Abstract][Full Text] [Related]
8. Distinctly altered gut microbiota in the progression of liver disease.
Xie G; Wang X; Liu P; Wei R; Chen W; Rajani C; Hernandez BY; Alegado R; Dong B; Li D; Jia W
Oncotarget; 2016 Apr; 7(15):19355-66. PubMed ID: 27036035
[TBL] [Abstract][Full Text] [Related]
9. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
[TBL] [Abstract][Full Text] [Related]
10. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
Golonka RM; Vijay-Kumar M
Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
[TBL] [Abstract][Full Text] [Related]
11. Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma.
Liu B; Zhou Z; Jin Y; Lu J; Feng D; Peng R; Sun H; Mu X; Li C; Chen Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996812
[TBL] [Abstract][Full Text] [Related]
12. COX2 regulates senescence secretome composition and senescence surveillance through PGE
Gonçalves S; Yin K; Ito Y; Chan A; Olan I; Gough S; Cassidy L; Serrao E; Smith S; Young A; Narita M; Hoare M
Cell Rep; 2021 Mar; 34(11):108860. PubMed ID: 33730589
[TBL] [Abstract][Full Text] [Related]
13. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
[TBL] [Abstract][Full Text] [Related]
14. The role of immune cells in the liver tumor microenvironment: an involvement of gut microbiota-derived factors.
Kamiya T; Ohtani N
Int Immunol; 2022 Sep; 34(9):467-474. PubMed ID: 35652367
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway.
Xia S; Ma J; Bai X; Zhang H; Cheng S; Zhang M; Zhang L; Du M; Wang Y; Li H; Rong R; Shi F; Yang Q; Leng J
Oncol Rep; 2014 Oct; 32(4):1521-30. PubMed ID: 25109834
[TBL] [Abstract][Full Text] [Related]
16. Diet-Induced Obesity Enhances Progression of Hepatocellular Carcinoma through Tenascin-C/Toll-Like Receptor 4 Signaling.
Benbow JH; Thompson KJ; Cope HL; Brandon-Warner E; Culberson CR; Bossi KL; Li T; Russo MW; Gersin KS; McKillop IH; deLemos AS; Schrum LW
Am J Pathol; 2016 Jan; 186(1):145-58. PubMed ID: 26603137
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
Boursier J; Diehl AM
Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
[TBL] [Abstract][Full Text] [Related]
18. Sex-dependent effects on gut microbiota regulate hepatic carcinogenic outcomes.
Xie G; Wang X; Zhao A; Yan J; Chen W; Jiang R; Ji J; Huang F; Zhang Y; Lei S; Ge K; Zheng X; Rajani C; Alegado RA; Liu J; Liu P; Nicholson J; Jia W
Sci Rep; 2017 Mar; 7():45232. PubMed ID: 28345673
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carcinoma.
Thilakarathna WPDW; Rupasinghe HPV; Ridgway ND
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807605
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis.
Xie G; Wang X; Huang F; Zhao A; Chen W; Yan J; Zhang Y; Lei S; Ge K; Zheng X; Liu J; Su M; Liu P; Jia W
Int J Cancer; 2016 Oct; 139(8):1764-75. PubMed ID: 27273788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
